Memantine Disrupts Motor Coordination through Anxiety-like Behavior in CD1 Mice

Area of Science:

• Neuroscience
• Pharmacology

Background:

• Memantine is FDA-approved for Alzheimer's disease, targeting NMDA receptors to reduce neurodegeneration.
• Previous studies suggest memantine's potential neuroprotective effects in cerebellar conditions like spinocerebellar ataxia type-1 (SCA1).
• The impact of NMDA receptor blockers on anxiety necessitates careful evaluation of memantine's side effects.

Purpose of the Study:

• To investigate the chronic effects of memantine on anxiety-related behaviors and motor performance in CD1 mice.
• To assess potential adverse effects of memantine beyond its known therapeutic actions.

Main Methods:

• Chronic administration of memantine to CD1 mice over a 9-week period.
• Evaluation of rotarod performance to assess motor coordination and balance.
• Assessment of anxiety-related behaviors using tests such as the tail suspension test.

Main Results:

• Memantine-treated mice showed impaired adaptation to anxiety-provoking situations, significantly affecting rotarod performance.
• Increased signs of behavioral despair were observed in the tail suspension test.
• These findings suggest memantine may induce deleterious effects related to stress and adaptation.

Conclusions:

• Chronic memantine use may lead to maladaptive responses to stress, impacting motor function assessments.
• The observed behavioral changes warrant careful consideration during clinical trials involving memantine.
• Further research is needed to fully understand the side effect profile of memantine in diverse patient populations.